Florin Gabriel Panculescu

Dr. Florin Gabriel Panculescu

Ovidius University, Constanţa, Romania
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ISIoana Livia Suliman
Ioana Livia Suliman
Florin Gabriel PanculescuFlorin Gabriel Panculescu
Florin Gabriel Panculescu
DFDragos Fasie
Dragos Fasie
BCBogdan Cimpineanu
Bogdan Cimpineanu
AAAndreea Alexandru
Andreea Alexandru
LTLiliana Ana Tuta
Liliana Ana Tuta
This systematic review investigates the role of the gut microbiota in patients with advanced chronic kidney disease (CKD), specifically stages 4 and 5. Increasing evidence suggests that dysbiosis—an alteration in the normal balance of gut microbial populations—is not merely a secondary consequence of renal decline but a significant driver of disease progression. Such microbial imbalances are closely linked to a range of CKD-associated complications, including systemic inflammation, accumulation of uremic toxins, and heightened cardiovascular risk. Using PRISMA 2020 guidelines, we analyzed 87 peer-reviewed studies published between 2019 and 2025. The review revealed a consistent decline in beneficial microbes such as short-chain fatty acid-producing bacteria were markedly reduced, while populations of uremic toxin-generating microbes were notably increased. This microbial imbalance was associated with elevated concentrations of indoxyl sulfate and p-cresyl sulfate, heightened systemic inflammation, and impaired intestinal barrier integrity. Five conceptual frameworks—including the gut—kidney axis and endotoxemia—inflammation loop—were discussed. Ten microbiome assessment tools were reviewed, including 16S rRNA sequencing and LC-MS/MS for uremic toxin detection. Although probiotics, prebiotics, and synbiotics are gaining attention as potential therapeutic options, questions remain regarding their long-term efficacy and incorporation into standard clinical practice. Increasing scientific evidence underscores the gut microbiome’s pivotal role in CKD progression and management, reinforcing the need for carefully designed, long-term interventions aimed at restoring a healthier microbial balance to support renal function.

28 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ATAndreea Elena Topa
Andreea Elena Topa
CIConstantin Ionescu
Constantin Ionescu
APAnca Daniela Pinzaru
Anca Daniela Pinzaru
EMElena Mocanu
Elena Mocanu
AIAna-Maria Iancu
Ana-Maria Iancu
SCSIMONA CLAUDIA CAMBREA
SIMONA CLAUDIA CAMBREA
Background/Objectives: Urinary tract infections (UTIs) represent a significant public health challenge, with Escherichia coli being the primary causative pathogen. The rise in antimicrobial resistance (AMR), further intensified by shifts in antibiotic prescribing practices during and after the COVID-19 pandemic, poses substantial difficulties in treatment optimization and clinical management. Methods: This retrospective study analyzed 644 E. coli strains from urine samples collected in a southeastern Romanian hospital during two periods: pre-pandemic (2018–2019, N = 361) and post-pandemic (2023–2024, N = 283). Antimicrobial susceptibility was assessed using the VITEK automated system for key antibiotic classes. Results: A significant increase in fluoroquinolone resistance was observed, especially for ciprofloxacin (p = 0.02), alongside rising ceftriaxone resistance (p = 0.004), suggesting the spread of ESBL-producing strains. Resistance to trimethoprim/sulfamethoxazole, ampicillin, and amoxicillin/clavulanic acid remained high, limiting their empirical use. Carbapenem resistance was low (p > 0.1), while nitrofurantoin and fosfomycin retained high efficacy (p = 0.26 and p = 0.64). Conclusions: The post-pandemic period showed a concerning rise in resistance to fluoroquinolones and third-generation cephalosporins, highlighting the need for stricter antimicrobial stewardship. Carbapenems remain effective for severe infections, while nitrofurantoin and fosfomycin are reliable first-line options for uncomplicated UTIs. Continuous AMR surveillance is essential to optimize treatment and curb multidrug-resistant strains.

Verified
Journal Article
Open access
PDF file
APAnca Daniela Pinzaru
Anca Daniela Pinzaru
ALAncuta Lupu
Ancuta Lupu
TCTatiana Chisnoiu
Tatiana Chisnoiu
GBGinel Baciu
Ginel Baciu
ABAlexandru Paul Baciu
Alexandru Paul Baciu
CMCristina Maria Mihai
Cristina Maria Mihai
Hyperglycemia significantly initiates oxidative stress in children diagnosed with type 1 diabetes (T1DM). This study investigates the differences in oxidative stress markers between pediatric patients with T1DM and those experiencing transient hyperglycemia. In this case–control study, 42 children diagnosed with T1DM, according to ISPAD (International Society for Pediatric and Adolescent Diabetes), and their healthy counterparts, aged 1–6 years old, participated. Blood samples were analyzed for oxidative stress biomarkers such as malondialdehyde (MDA) and glutathione peroxidase (GPx). There was no statistically significant association found between the A1c % and age, BMI, and insulin dose (p > 0.05). A negative correlation was found between Se, Zn, cholesterol, GSH, and GPx (p < 0.05), as well as a statistically meaningful positive correlation with the A1c % (p < 0.001). GSH exhibited a statistically significant negative correlation (p < 0.001) with diabetic group. In comparison to control participants, plasma MDA levels (1.3 ± 0.36 µmol/L) had already increased significantly. MDA did correlate in a diabetic group with triglyceride levels (p > 0.0001) or total cholesterol. In the healthy group, the cholesterol levels were normal and apparently did not influence MDA levels. The oxidative state remained unchanged in the healthy participants experiencing temporary hyperglycemia, even though T1DM altered the link between selenium, zinc, and lipids.

Verified
Journal Article
Open access
PDF file
DFDragos Fasie
Dragos Fasie
ISIoana Livia Suliman
Ioana Livia Suliman
Florin Gabriel PanculescuFlorin Gabriel Panculescu
Florin Gabriel Panculescu
BCBogdan Cimpineanu
Bogdan Cimpineanu
AAAndreea Alexandru
Andreea Alexandru
LTLiliana Ana Tuta
Liliana Ana Tuta
This systematic review examines chronic kidney disease-associated pruritus (CKD-aP) as a complex clinical manifestation in patients undergoing hemodialysis. Traditionally considered a secondary symptom of end-stage renal disease, emerging evidence now positions CKD-aP as a multidimensional disorder with substantial pathogenic influence on patient outcomes. Using the PRISMA 2020 methodology, we critically evaluated 54 peer-reviewed studies published between 2020 and 2025. Our synthesis highlights a convergence of five mechanistic frameworks underpinning CKD-aP: elevated levels of uremic toxins originating from gut microbial dysbiosis, immune activation driven by IL-31 and other pro-inflammatory cytokines, heightened peripheral and central neural sensitization, dysregulation of endogenous opioid receptor pathways favoring μ-receptor activation, and xerosis-related epidermal barrier dysfunction. These mechanisms contribute to a systemic cycle of microinflammation, pruritogenic signaling, and neural hyperexcitability. We also identified and compared validated assessment tools—including the NRS, VAS, Skindex-10, and the UP-Dial scale—that facilitate standardized quantification of disease burden. While available treatments such as gabapentinoids and phototherapy offer partial relief, targeted therapies—including κ-opioid receptor agonists—represent a major advancement, although long-term effectiveness and accessibility remain under investigation. Growing scientific consensus establishes CKD-aP as a priority therapeutic target in hemodialysis care, underscoring the need for integrated, mechanism-based management strategies to improve quality of life and clinical outcomes. This work represents a narrative systematic review, integrating evidence from mechanistic, translational, and clinical studies to critically examine the biological pathways underlying CKD-associated pruritus.

29 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ISIoana Livia Suliman
Ioana Livia Suliman
Florin Gabriel PanculescuFlorin Gabriel Panculescu
Florin Gabriel Panculescu
BCBogdan Cimpineanu
Bogdan Cimpineanu
SPStere Popescu
Stere Popescu
DFDragos Fasie
Dragos Fasie
AAAndreea Alexandru
Andreea Alexandru
Background: End-stage renal disease (ESRD) patients on haemodialysis present a high burden of cardiovascular comorbidities and require anticoagulation, which increases bleeding risk. Methods: We performed a retrospective observational study (2021–2024) in the Haemodialysis Centre of The Clinical Emergency Hospital of Constanta County, Romania, including 50 adults with stage G5 CKD on haemodialysis for ≥3 months and receiving anticoagulant therapy. We collected from electronic medical records detailed demographic data (age, sex, place of residence), comorbidities (hypertension, atrial fibrillation, ischaemic heart disease, diabetes, deep-vein thrombosis, stroke, myocardial infarction, pulmonary embolism, cirrhosis), lifestyle factors (smoking and alcohol consumption), vascular access type (arteriovenous fistula or central venous catheter) and laboratory parameters (haemoglobin, haematocrit, creatinine, albumin, total protein, electrolytes, LDL- and HDL-cholesterol, total cholesterol, INR, APTT, D-dimer, BNP, CK-MB, troponin). All laboratory units were standardised and checked for plausibility. Results: Median age was 71 years; 48% were female. The most common comorbidities were: hypertension (100%), atrial fibrillation (100%) and ischaemic heart disease (62–81%). Patients exhibited severe anaemia (mean Hb ~9.7 g/dL), nephrotic-range proteinuria, hypoalbuminaemia, and impaired coagulation profiles (INR ~1.8–1.9; prolonged APTT in men). Female patients had higher platelet counts and D-dimer levels, suggesting a stronger prothrombotic profile, while males showed longer APTT. Cardiovascular strain was reflected by elevated BNP in men and also troponin/CK-MB. Correlations included smoking with leukocytosis, alcohol with increased urine density, diabetes with higher urea and lower protein, and subtherapeutic INR in cerebrovascular disease. Conclusions: Patients with ESRD on haemodialysis and anticoagulant therapy display a complex interplay of cardiovascular comorbidities, anemia, overlapping thrombotic and bleeding risks, with sex-specific differences. Therefore, systematic monitoring of proteinuria, haemoglobin, D-dimer, and coagulation markers is crucial to balance thrombotic and bleeding risks. Objective: To characterise the clinical and paraclinical profile and comorbidity–laboratory correlations of ESRD patients undergoing haemodialysis and anticoagulant therapy.

15 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ISIoana Livia Suliman
Ioana Livia Suliman
LTLiliana Ana Tuta
Liliana Ana Tuta
Florin Gabriel PanculescuFlorin Gabriel Panculescu
Florin Gabriel Panculescu
AAAndreea Alexandru
Andreea Alexandru
DFDragos Fasie
Dragos Fasie
IBIon Bordeianu
Ion Bordeianu
Background: Anticoagulation in patients with advanced chronic kidney disease (CKD) and atrial fibrillation (AF) remains challenging due to the concurrent risks of thrombosis and bleeding driven by endothelial dysfunction, uremic inflammation, and impaired hemostasis. Evidence comparing vitamin K antagonists (VKAs) with direct oral anticoagulants (NOACs) in this high-risk population, particularly in dialysis, is still limited. Methods: We conducted a single-center, retrospective observational study including 93 patients with CKD stages 4–5 and AF treated between January 2021 and February 2025. Fifty patients received apixaban (2.5–5 mg twice daily), and forty-three received acenocoumarol with a target INR of 2.0–3.0. Thirty-eight patients (41%) were on maintenance hemodialysis. Demographics, comorbidities, and risk scores (CHA2DS2-VASc and HAS-BLED) were analyzed. Bleeding events were classified per ISTH criteria. Statistical comparisons used t-tests and χ2 tests, with p < 0.05 considered significant. Results: The mean age was 67.8 ± 9.1 years, and 51.6% were male. Major bleeding occurred in 9.7%, minor in 15.8%, and overdose-related bleeding in 10.0% of patients. The overall bleeding rate was significantly lower in the apixaban group (16.0%) than in the acenocoumarol group (53.5%; p = 0.01). No thromboembolic events were observed in either group. Dialysis patients had higher bleeding rates overall (13.2% vs. 7.4%), mainly among those on VKAs. The HAS-BLED score moderately correlated with bleeding incidence (r = 0.43, p < 0.01). Conclusions: Apixaban provided comparable thromboembolic protection with significantly fewer bleeding events than acenocoumarol, including in patients on dialysis. These findings support apixaban as a safer and more practical anticoagulant option in advanced CKD, consistent with its limited renal clearance and reduced influence on the inflammation–coagulation axis. Further multicenter prospective studies are warranted to validate these real-world results.